Ad
related to: aspirin and clopidogrel post stroke medication management guideline tool
Search results
Results from the WOW.Com Content Network
In the 2008, guidelines for stroke management from the European Stroke Organization, [3] triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid (ASA)(Aspirin) plus dipyridamole, or clopidogrel alone for secondary prevention of atherothrombotic stroke.
Aside from aspirin, three antiplatelet agents taken by mouth have been approved for use in acute coronary syndromes, clopidogrel, ticagrelor and prasugrel; all reduce platelet aggregation by inhibiting the P2Y 12 receptor, a type of adenosine phosphate receptor, on the surface of platelets. Not all three of them are equally indicated in all ...
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [10] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [10]
The accepted management of unstable angina and acute coronary syndrome is therefore empirical treatment with aspirin, a second platelet inhibitor such as clopidogrel, prasugrel or ticagrelor, and heparin (usually a low-molecular weight heparin), with intravenous nitroglycerin and opioids if the pain persists.
The antiplatelet medications, aspirin and clopidogrel, are both recommended for secondary prevention of stroke after high-risk TIAs. [22] [21] [23] The clopidogrel can generally be stopped after 10 to 21 days. [23] An exception is TIAs due to blood clots originating from the heart, in which case anticoagulants are generally recommended. [21]
NSAIDS (e.g.: aspirin, ibuprofen, diclofenac, naproxen) Other anticoagulants or antiplatelet drugs; Medications that may decrease antiplatelet drug effect: [3] Carbamazepine; Erythromycin; Fluconazole; Omeprazole; Use of NSAIDs as part of dental management of patients with vascular disease should be discouraged as NSAIDs have antiplatelet effect.
In the US, ticagrelor is indicated to reduce the risk of stroke in people with acute ischemic stroke or high-risk transient ischemic attack. [5]In the EU, ticagrelor, co-administered with acetylsalicylic acid (aspirin), is indicated for the prevention of atherothrombotic events in adults with acute coronary syndromes or a history of myocardial infarction and a high risk of developing an ...
Key medications with strong evidence of benefit include aspirin, or alternatively clopidogrel. [45] These medications help to prevent clots in the coronary artery and the occlusion which can lead to a heart attack. [46] Angiotensin-converting enzyme inhibitors are indicated in individuals with diabetes, kidney disease, and hypertension. [45]
Ad
related to: aspirin and clopidogrel post stroke medication management guideline tool